Context Therapeutics (CNTX) Operating Leases (2022 - 2026)

Context Therapeutics has disclosed Operating Leases across 5 years of filings, most recently posting $300000.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $300000.0, up 263.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $300000.0 (up 263.16% YoY), and the FY2024 annual result was $112064.0, changed N/A from the prior year.
• Operating Leases came in at $300000.0 for Q1 2026 at Context Therapeutics, up from $100000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $300000.0 in Q1 2026 to a low of $7967.0 in Q2 2022.
• The 5-year median for Operating Leases is $91304.0 (2022), against an average of $101289.6.
• Across the five-year window, Operating Leases sank 68.33% in 2023 and jumped 263.16% in 2026, its largest moves.
• Context Therapeutics' Operating Leases stood at $55000.0 in 2022, then sank by 85.51% to $7967.0 in 2023, then soared by 1306.6% to $112064.0 in 2024, then declined by 10.77% to $100000.0 in 2025, then soared by 200.0% to $300000.0 in 2026.
• The last three Operating Leases figures came in at $300000.0 (Q1 2026), $100000.0 (Q3 2025), and $200000.0 (Q2 2025), per Business Quant data.